Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...

Editas Medicines has signed a $238 million biobucks pact to combine Genevant Science’s lipid nanoparticle (LNP) tech with the ...

Boston Scientific collected a set of FDA green lights for an update to its pulsed field ablation system for atrial ...

Italy’s Angelini Pharma has signed a $360 million biobucks pact centered on a phase 1-stage brain health drug from South ...

Horizon Surgical Systems, a startup developing automated, artificial intelligence-powered robotic tools for eye surgery, has ...

Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

After launching on its maiden voyage in April, Seaport Therapeutics and its crew of Karuna veterans have loaded up with $225 ...

| Now’s the time to rethink clinical trials with real-world data (RWD). Discover strategies to optimize your protocols and ...